Green tea and bone health: Evidence from laboratory studies

Chwan-Li Shen a, b, *, James K. Yeh c, Jay J. Cao d, Ming-Chien Chyu e, f, Jia-Sheng Wang g

a Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
b Lauren W. Bush Institute for Women's Health, Texas Tech University Health Sciences Center, Lubbock, TX, USA
c Applied Bench Core Laboratory, Winthrop-University Hospital, Mineola, NY, USA
d USDA ARS Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA
e Department of Mechanical Engineering, Texas Tech University, Lubbock, TX, USA
f Graduate Healthcare Engineering Option, Texas Tech University, Lubbock, TX, USA
g Department of Environmental Health Science, University of Georgia, Athens, GA, USA

A R T I C L E   I N F O
Article history:
Received 10 January 2011
Received in revised form 23 March 2011
Accepted 25 March 2011

Keywords:
Tea polyphenols
Antioxidant
Bone mineral density
Osteoporosis
Human
Rat
Cell

A B S T R A C T
Osteoporosis is a major health problem in the elderly. Epidemiological evidence has shown an association between tea consumption and the prevention of bone loss in the elderly population. Ingestion of green tea and green tea bioactive compounds may be beneficial in mitigating bone loss of this population and decreasing their risk of osteoporotic fractures. This review describes the effect of green tea with its bioactive components on bone health with an emphasis on the following: (i) the etiology of osteoporosis, (ii) evidence of osteo-protective impacts of green tea on bone mass and microarchitecture in various bone loss models in which induced by aging, sex hormone deficiency, and chronic inflammation, (iii) discussion of impacts of green tea on bone mass in two obesity models, (iv) observation of short-term green tea supplementation given to postmenopausal women with low bone mass, (v) possible mechanisms for the osteo-protective effects of green tea bioactive compounds, and (vi) a summary and future research direction of green tea and bone health.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction
The trend of increased life expectancy is accompanied with an increase in the prevalence of osteoporosis and concomitant complications in the elderly population. Osteoporosis, a degenerative bone disease, is characterized by low bone mass and microstructural deterioration of bone tissue that results in bone fragility and an increased susceptibility to fractures [1]. Hip fracture is the most severe consequence of osteoporosis, resulting in decreased activities of daily living, lowered quality of life, and increased mortality [2].

Osteoporosis occurring in postmenopausal women and elderly men represents a major health and economic burden in our fast growing elderly population. In the United States, approximately 44 million or 55 percent of the people 50 and older have osteoporosis or low bone mass [3]. It is estimated that by 2020, there will be over 61 million women and men in this age category that are affected [3]. By the year 2025, experts predict that the costs of osteoporosis-related expenses will rise to approximately $25.3 billion [4].

Although there are a variety of agents available for the prevention and/or treatment of low bone mass (also called osteopenia) and osteoporosis, some patients select complementary and alternative therapies, such as dietary supplements or functional foods, for this purpose [5]. Tea, the dried leaves of the Camellia sinensis species of the Theaceae family, is a popular beverage with an annual production of three billion kilograms worldwide [6]. In the past decade, epidemiological evidence has shown an association between tea consumption and the prevention of age-related bone loss in the elderly population. The impact of tea consumption on bone mass and risk of osteoporotic fractures in humans has been comprehensively reported in our previous review paper and we found that among different forms of tea (green tea, black tea, white tea, and Oolong tea), drinking green tea and/or ingesting green tea bioactive compounds may mitigate bone loss in elderly women and men, thereby decreasing their risk of osteoporotic fractures.
Therefore, in this review, we focus on animal studies in various models with an emphasis on bone health. In addition, a short-term translational study employing green tea supplement given to post-menopausal women with low bone mass is also discussed.

2. Bone biology and metabolic disorders

Bone is a highly specialized support tissue which is characterized by its rigidity and hardness. As a material, bone has strength similar to cast iron, while its density is as low as wood. Calcium and phosphorus mineral crystals are deposited around the protein strands. The flexible protein strands provide the tensile strength that holds the structure together and the brittle minerals provide the solid structure. The two main categories of bone cells are osteoblasts that form the bone and osteoclasts that resorb (dissolve) the bone. The combined and cooperative activities of osteoblasts and osteoclasts result in a bone architecture that provides mechanical support and protection for the body. In addition, bone serves as a vital reservoir of minerals, principally calcium and phosphorus, necessary for maintaining normal cellular, neurologic, and vascular activities of the body [8].

Table 1
Effect of green tea supplementation on bone health in various animal models.

<table>
<thead>
<tr>
<th>First author, yr reference</th>
<th>Model</th>
<th>Animals</th>
<th>Treatments</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen, 2008 [16] Shen, 2010 [21]</td>
<td>Aging-induced bone loss model Aging plus estrogen deficiency-induced bone loss model</td>
<td>Sham and OVX, 14-mo-old female F344 × B6F1/NIA rats</td>
<td>GTP: 0.1% or 0.5% (wt/vol) in drinking water for 16 weeks</td>
<td>† Femur BMD&lt;sup&gt;a&lt;/sup&gt; † Serum OC, ↓ serum TRAP, ↓ urinary Ca via ↓ 8-OHdG (a marker of oxidative stress DNA damage), ↓ GPX activity (a marker of antioxidant capacity), and ↑ SOD1 expression (a marker of antioxidant capacity)</td>
</tr>
<tr>
<td>Shen, 2009 [17]</td>
<td>Aging-induced bone loss model Aging plus estrogen deficiency-induced bone loss model</td>
<td>Sham and OVX, 14-mo-old female F344 × B6F1/NIA rats</td>
<td>GTP: 0.1% or 0.5% (wt/vol) in drinking water for 16 weeks</td>
<td>† BV/TV, BFR, Tb.N and Tb.Th of proximal tibia&lt;sup&gt;b&lt;/sup&gt; † Cortical thickness and area of femur&lt;sup&gt;d&lt;/sup&gt; ↓ Tb.Sp and bone erosion of proximal tibia&lt;sup&gt;b&lt;/sup&gt; ↓ Endocortical bone eroded surface of tibia shaft&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Shen, 2010 [23]</td>
<td>Aging-induced bone loss model Aging plus testosterone deficiency-induced bone loss model</td>
<td>Sham and ORX, 15-mo-old male F344 rats</td>
<td>GTP: 0.5% (wt/vol) in drinking water for 16 weeks</td>
<td>† BV/TV, Tb.Th and bone formation rates in both proximal tibia and periosteal tibial shafts&lt;sup&gt;b&lt;/sup&gt; ↓ Eroded surface in both proximal tibia and endocortical tibial shafts&lt;sup&gt;b&lt;/sup&gt; via ↑ GPX activity</td>
</tr>
<tr>
<td>Shen, 2010 [25]</td>
<td>Chronic inflammation (LPS)-induced bone loss model</td>
<td>3-month-old female CD rats</td>
<td>GTP: 0.5% (wt/vol) in drinking water for 12 weeks</td>
<td>† Femur BMD&lt;sup&gt;d&lt;/sup&gt; † Serum OC, ↓ serum TRAP via ↓ 8-OHdG production and ↓ COX-2 and TNF-α mRNA expression (markers of pro-inflammatory cytokine)</td>
</tr>
<tr>
<td>Shen, 2010 [26]</td>
<td>Chronic inflammation (LPS)-induced bone loss model</td>
<td>3-month-old female rats</td>
<td>GTP: 0.5% (wt/vol) in drinking water for 12 weeks</td>
<td>† BV/TV, Tb.N and Tb.Th of femur&lt;sup&gt;d&lt;/sup&gt; and tibia&lt;sup&gt;b&lt;/sup&gt; ↓ Periosteal bone formation rate in tibial shafts&lt;sup&gt;b&lt;/sup&gt; ↓ Tb.Sp in proximal tibia and eroded surface in endocortical tibial shafts&lt;sup&gt;b&lt;/sup&gt; ↓ Osteoclastic number of tibia shafts&lt;sup&gt;b&lt;/sup&gt; ↓ Bone strength of femur via ↓ TNF-α protein expression in trabecular bone</td>
</tr>
<tr>
<td>Nakamura, 2010 [27]</td>
<td>Topically LPS-infected gingival inflammation model</td>
<td>7-wk-old male BALB/c mice</td>
<td>GTC: injection (10 μg/mL) into infected gingival, once every 48 h for 10 times</td>
<td>↓ LPS-induced alveolar bone resorption&lt;sup&gt;b&lt;/sup&gt;↓ (as shown by increased TRAP-positive osteoclasts) via ↓ IL-1β production (a marker of pro-inflammatory cytokine) or ↓ osteoclastogenesis directly</td>
</tr>
<tr>
<td>Maruyama, 2010 [28]</td>
<td>Topically LPS-infected periodontal inflammation model</td>
<td>8-wk-old male Wistar rats</td>
<td>GTC: 1% in dentifrice for the last 4 weeks in a total of 8 weeks study period</td>
<td>↓ LPS-induced inflammation cell infiltration in connective tissue via ↓ hexanoyl-lysine (a marker of lipid peroxidation), nitrotyrosine (a maker of oxidative protein damage), and TNF-α (a marker of pro-inflammatory cytokines) No impact on LPS-induced bone resorption</td>
</tr>
<tr>
<td>Shen, 2010 [30]</td>
<td>High-fat-diet induced obesity model</td>
<td>3-mo-old CD female rats fed a high-fat diet for 4 months</td>
<td>GTP: 0.5% (wt/vol) in drinking water 16 weeks</td>
<td>↑ Femur BMC and BMD&lt;sup&gt;d&lt;/sup&gt; ↓ Weight gain (↓ fat mass and ↑ fat-free mass) ↓ Serum leptin production via ↑ GPX activity</td>
</tr>
</tbody>
</table>
Both osteoblastic and osteoclastic cells regulate bone metabolism, and both cell types are involved in the development of osteoporosis [8]. Osteoblasts, the bone-forming cells, locate near the surface of the bone and produce cytokines that affect osteoclasts. Cytokines, including macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL), are both essential for osteoclast differentiation, function, and survival [9,10]. Osteoclasts, the bone-resorbing multinucleated cells, are tightly attached to mineralized bone surfaces through their integrins and form resorption lacuna by secreting protons, proteases, and superoxide through ruffled borders [11,12]. Bone resorption by activated osteoclasts with subsequent deposition of a new matrix by osteoblasts causes the formation of bone structure and bone remodeling [8]. Imbalance between bone formation and bone resorption is the key pathophysiological event in many metabolic bone disorders in adult humans, including osteoporosis, which results in bone loss [13].

3. Evidence of osteo-protective effects of green tea in animals

All but one animal studies support that green tea may benefit bone health by mitigating bone loss due to aging, aging plus sexual hormone deficiency, or chronic inflammation, or by preserving bone mass due to obesity, as summarized in Table 1.

3.1. Female rat models of osteoporosis

The models of intact and ovariectomized (OVX) aged female rats have been widely used to study both aging and ovarian hormone deficiency-induced bone loss, respectively. A number of studies show that both intact and OVX models have been recognized as appropriate female rat models to study premenopausal and postmenopausal women with low bone loss [14] for the following reasons: (i) aged female rats have completed bone growth and commenced bone loss, while bone growth is still in progress in young rats [14]. Sham-operated aged female rats were used as an established model of premenopausal women, and (ii) an OVX rat properly simulates estrogen-deficient condition and has been widely used as an animal model for postmenopausal osteoporosis [15].

Animal studies conducted in our laboratory have shown that green tea polyphenols (GTP) have positive effects on bone mass and microarchitecture in both models of bone loss [16,17]. The findings indicated that GTP prevented the aging-induced as well as aging plus estrogen deficiency-induced reduction in femoral bone mass (i.e., bone mineral content (BMC) and density (BMD)) in sham rats and OVX rats, respectively. Serum osteocalcin (a bone formation biomarker) was elevated by the GTP treatment, while serum tartrate-resistant acid phosphatase (TRAP, a bone resorption biomarker) was suppressed by the GTP treatment.

In that study, female F344 × BFN1/NIA rats (14-month-old) were divided into seven groups: baseline group (euthanized at the beginning of study), sham operated (SH), SH + 0.1% GTP (weight/volume), SH + 0.5% GTP, OVX, OVX + 0.1% GTP, and OVX + 0.5% GTP. Treatments were started two weeks after surgery and continued for 16 weeks. Rats were given 0.1% or 0.5% concentration of GTP in drinking water daily to mimic human consumption of green tea of 1 or 4 cups a day, respectively [18–20]. These dosages (1 and 4 servings a day, 1 serving = 120 ml) are feasible for human daily consumption. GTP has purity higher than 98%. Every 1000 mg of GTP contained 480 mg of EGCG, 160 mg of epicatechin gallate (ECG), 60 mg of epicatechin (EC), 103 mg of epigallocatechin (EGC), and 30 mg of catechin according to the high performance liquid chromatography coupled with electrochemical detection (HPLC-ECD) and HPLC-UV analyses [16].

Aging significantly reduced the bone mass of the femur and deteriorated the bone microarchitecture of the tibia. Aging plus estrogen deficiency produced a more detrimental effect on bone mass and microarchitecture than aging alone [16]. The same study demonstrated beneficial effects of GTP supplementation in preserving bone mass of the femur [16] and improving cancellous and cortical microstructure of the tibia in both SH and OVX rats by enhancing bone formation and suppressing bone erosion [17]. The impact of GTP on bone parameters was dose-dependent. For example, GTP, as low as 0.1%, was effective in restoring femoral BMC in the SH group, when compared to the baseline group. SH + 0.5% GTP treatment even completely prevented aging-induced bone loss. The results showed that urinary 8-hydroxy-2′-deoxyguanosine (a biomarker of oxidative stress) and urinary calcium were decreased, and the liver glutathione peroxidase activities [16] and superoxide dismutase 1 expression (indicator of antioxidant capacity) [21] were increased as a result of SH and OVX rats receiving GTP supplementation [16,17]. The authors concluded that the bone protective mechanism of GTP, in part, may be due to the ability of GTP to suppress oxidative stress and increase antioxidant capacity. Moreover, it was noted by the authors that such an osteo-protective effect of GTP on OVX rats appears to be mild compared to that on SH rats.

From the same study, the impact of GTP on bone mass in OVX rats may be independent of estrogen level and showed no changes in serum estradiol concentration of rats [16]. Interestingly, the sham-operated groups (estrogen adequate) with GTP supplementation only showed an effect on uterine weight, not on serum estradiol concentration, a result possibly associated with its weak binding affinity for estrogen receptor(s) (ER), especially ER-α and ER-β [22].

3.2. Male rat models of osteoporosis

Similar to the above findings observed in an animal model for postmenopausal osteoporosis, Shen et al. also reported that GTP supplementation improves bone microstructure in aged orchidec-
tomized (ORX) rat model, a model for senile male osteoporosis [23]. In that study, fifty 15–month-old aged F344 male rats were assigned into SH, SH + 0.5% GTP, ORX, and ORX + 0.5% GTP groups with 10 rats per treatment group. Same type and concentration of GTP (0.5%, wt/vol in drinking water) has been used in our female rat models of osteoporosis [16,17]. The remaining 10 rats without any surgical procedures formed the baseline group and were euthanized before the beginning of the study. GTP supplementation was started two weeks after surgery and continued for 16 weeks. Femoral bones were collected for bone scan using dual energy X-ray absorptiometry and micro-computed tomography, as well as for bone strength, and trabecular bones were collected for microarchitectural properties using bone histomorphometric analyses. Orchidectomy reduced serum testosterone, BMD, and bone strength. Orchidectomy also decreased trabecular bone volume, number and thickness in distal femur and proximal tibia, and bone formation rate in trabecular bone of proximal tibia, but increased bone formation rates in endocortical tibial shaft [23].

The results of this study showed that supplementation of GTP was effective in preventing both the aging- and aging plus ORX-induced loss of bone volume in both distal femur and tibia, resulting in improved bone strength. Similar observations were made in trabecular number and thickness where GTP supplementation was protective against the loss of trabecular number and thickness as a result of aging or aging plus ORX. From the same study, authors also reported that GTP supplementation significantly increased bone formation rates, but suppressed bone erosion in both proximal tibia and endocortical tibial shaft of aged ORX rats. Such a bone-protective effect of GTP may, in part, due to the elevation of antioxidant potential, as shown in the greater activity of glutathione peroxidase in liver. These observations were similar to the earlier findings in a female rat model of bone loss [16].

3.3. Chronic inflammation-induced bone loss models

Emerging data also indicate that GTP is very effective in preserving bone mass in various models of chronic inflammation-induced bone loss. Green tea polyphenols have been found to counteract inflammation-induced bone loss in a recent animal study by Shen et al. [25,26]. In Shen et al.’s study, a 2 (placebo vs. lipopolysaccharide, LPS) × 2 (no GTP vs. 0.5% GTP in drinking water) factorial design was used with 40 female rats (3-month-old) assigned to 4 groups for 12 weeks. Same type and concentration of GTP (0.5%, wt/vol in drinking water) has been used in our female rat models of osteoporosis [16,17]. They reported that LPS administration resulted in a significant increase in the inflammation index as determined by the total white blood cell count, and accompanied by significant bone loss and bone microstructure deterioration. Bone loss was demonstrated by a decrease in BMD [25], accompanied by lower trabecular volume fraction, number, and thickness in the proximal tibia, and increased eroded surface and osteoclast number in the endocortical tibial shafts, as assessed by bone histomorphometry [26]. In addition, LPS administration also resulted in a lower osteocalcin concentration and a higher TRAP concentration compared to the placebo treatment [26].

After 12 weeks of treatment, supplementation of GTP (400 mg/kg body weight) in the drinking water significantly increased BMD, serum osteocalcin, as well as trabecular volume fraction and number in both femur and tibia, but decreased serum TRAP, eroded surface, and osteoclast number in endocortical tibial shafts [25,26]. This study demonstrated that GTP supplementation in drinking water for 12 weeks prevented trabecular bone loss due to increased bone turnover by LPS administration. From the same study, GTP supplementation was shown to suppress oxidative stress (as shown by decreased urinary 8-hydroxy-2-deoxyguanosine levels) and inflammation (as shown by suppressed mRNA expression of tumor necrosis factor-α and cyclooxygenase-2 in spleen). Authors concluded that GTP mitigates bone loss in a chronic-inflammation-induced bone loss model by reducing oxidative stress-induced damage and inflammation [25,26].

3.4. LPS-induced alveolar bone resorption model

Shen et al.’s study [25] is corroborated by the findings of Nakamura et al. [27] that topical application of green tea catechin (GTC) into LPS-treated gingivae of BALB/c mice significantly inhibited LPS-induced alveolar bone resorption. In that study, LPS or LPS with 1% Sunphenon BG (containing 91.3% polyphenol and 76.6% GTC, consisting of 45.9% EGC, 9.6% EGC, 8.6% ECG, 5.3% EC, and others, Taiyo Kagaku, Mie, Japan) was injected a total of 10 times, once every 48 h, into the gingivae of BALB/c mice [27]. Another group of mice, housed with free access to water containing 1% Sunphenon BG throughout the experimental period, were also injected with LPS in a similar manner.

LPS induced the alveolar bone resorption (as shown in increased TRAP-positive osteoclasts by immunohistological staining and quantification) and interleukin-1 beta (IL-1β) expression in gingival tissue. GTC by injection or oral administration to mice significantly inhibited LPS-induced alveolar bone resorption in mice. Authors concluded that such inhibitory impact of GTC on bone resorption is mediated by suppressing IL-1β expression or by directly inhibiting RANKL-induced osteoclastogenesis.

A recent study published by Maruyama et al. [28] using male Wistar rats also showed that supplementation of GTC in dentifrices suppresses gingival oxidative stress and periodontal inflammation. In that study, twenty-four 8-week-old male Wistar rats were randomly assigned into four groups of six rats each group: (1) control group receiving no treatment for 8 weeks, (2) periodontal inflammation group receiving inflammation for 8 weeks, (3) periodontal inflammation plus control dentifrice for 8 weeks and receiving control dentifrice to the gingival sulcus daily for the last 4 weeks, and (4) periodontal inflammation + 1% GTC (Sunphenon 100S; Taiyo Kagaku, Mie, Japan)—containing dentifrice group having experimental periodontal inflammation for 8 weeks and receiving topical application of a GTC-containing dentifrice to the gingival sulcus daily for the last 4 weeks. The Sunphenon 100S was composed of 18% EGC, 11.6% GCG, 4.6% ECG, 15.0% EGC, 14.8% GC, 7.0% EC, and 3% catechin.

After an 8-week inflammation period, periodontal inflammation caused alveolar bone loss and inflammatory cell infiltration in the connective tissue subjacent to the junctional epithelium of rats. Topical application of GTC-containing dentifrice suppressed such inflammatory cell infiltration, but had no effect on alveolar bone loss. The inhibitory effect on inflammation was demonstrated by decreased gingival oxidative stress and expression of pro-inflammatory cytokines.

Although green tea supplementation was shown to inhibit inflammation in these three different inflammation models, only two studies [25,27] demonstrated GTP’s ability to suppress bone resorption. The discrepancy may be explained by various animal models, various doses and length of green tea supplementation, different types of bones, and assessment of bone resorption (histomorphometric analysis in Shen et al., immunohistochemistic analysis in Nakamura et al., and histological analysis in Maruyama et al.).

3.5. Obesity models

Studies have shown that increased central body fat had a negative association with BMD in postmenopausal women, suggesting prevention of menopause-related osteoporosis through reducing centralized fat deposition [29]. Shen et al. [30] demonstrated that...
supplementation of GTP (0.5%, vol/wt) in drinking water for 16 weeks provided both anti-obesity and osteo-protective benefits in middle-aged, high-fat-diet-induced obese female rats. In that study, 3-month-old CD female rats were fed either a low-fat (LF) diet (n = 12) or a high-fat (HF) diet (n = 24) ad libitum for 4 months. Animals in the LF diet group continued on a LF diet for additional 4 months, while those in the HF diet group were divided into groups with or without 0.5% GTP in drinking water, in addition to a HF diet for another 4 months. Same type and concentration of GTP (0.5%, wt/vol in drinking water) has been used in our female rat models of osteoporosis [16,17]. Body composition including fat mass and fat-free mass was measured by bioimpedance spectroscopy. Femoral BMC and BMD were measured by dual-energy X-ray absorptiometry. Serum leptin and adiponectin (fat hormones) were also determined in these rats. After 4 months of treatment, compared to the LF diet, the HF diet increased body weight and fat mass and leptin, decreased fat-free mass, and had no impact on BMC, BMD, and serum adiponectin in rats. GTP supplementation was able to prevent weight gain (shown by decreased fat mass and increased fat-free mass), increased BMC and BMD, suppressed serum leptin, but had no influence on serum adiponectin in HF diet-induced obese rats. Authors concluded that GTP supplementation in drinking water for 4 months prevents weight gain and enhances bone matrix in rats, through improving antioxidant capacity (increased liver glutathione peroxidase) and modulating fat hormones (suppressed leptin) [30].

In an earlier study, Iwaniec et al. [31] also reported that green tea extract (GTE) supplementation to lean C57BL/6 wild type (WT) and genetically obese, leptin-deficient (ob/ob) male mice prevented weight gain. In that study, both five-week-old lean and ob/ob mice were assigned to powder diets containing GTE at 0, 1, or 2% (wt/wt) for 6 weeks. According to the results of HPLC-UV, the GTE contained 30% (wt/wt) catechins [consisting of 48% EGCG, 31% ECG, 13% EGC, and 8% EC] and 5.6 mg caffeine/100 mg GTE [31]. Rats were given 1% or 2% GTE in diet was equivalent to human consumption of green tea of 7 or 14 servings a day, respectively.

Femoral and lumbar vertebral bone volume and architecture were assessed by micro-computed tomography. Then, femoral bones were ashed to measure BMC and BMD. Compared to the WT mice, ob/ob mice had lower values for bone length, bone volume, and BMC of femur, but higher values for cancellous bone volume of lumbar vertebrae. GTE supplementation in the diets suppressed the rate of bone accumulation during growth, as shown by shorter length, reduced total and cortical bone volume, and cortical thickness, as well as decreased BMC of femur. The same study also showed that neither genotype nor treatment influenced femoral BMD, indicating normal mineralization during growth.

The discrepancy between these two models (Shen et al. [30] and Iwaniec et al. [31]) may be due to different dosage of green tea (~4 servings/day in Shen’s study vs. ~7–14 servings/day in Iwaniec’ study), different model of obesity (high-fat-diet induced obese model vs. genetically obese, leptin-deficient ob/ob mice model), and different age of animals (18 months old vs. 3 months old) reflecting different stages of bone metabolism (remodeling during aging vs. modeling during growth). Although green tea has been considered as a relatively safe beverage, a rich source of antioxidants, showing no serious side effect for up to 8 servings per day in humans, a high dosage of green tea may become a source of prooxidants that has a detrimental impact on bone matrix.

4. Implication of green tea’s osteo-protective effect in humans

In addition to the animal studies, the findings of our short-term 6-month clinical trial indicated that the consumption of GTP (500 mg per day) by postmenopausal women appeared to be safe, particularly in terms of liver and kidney functions [32]. In that study, 171 postmenopausal women with low bone mass (57.4 ± 6.8 yr, BMI 28.4 ± 5.3 kg/m²) were randomly assigned into 4 treatment groups for 24 weeks: (1) Placebo (500 mg medicinal starch/day), (2) GTP (500 mg GTP/day), (3) Placebo + Tai Chi (placebo plus Tai Chi exercise at 60 min/session, 3 sessions/week), and (4) GTP + Tai Chi (GTP plus Tai Chi exercise). After 24 weeks intervention, 21 participants dropped out (12% attrition rate) due to loss of interest or any other condition unrelated to the current study intervention. The compliance rates for study agents (both placebo and GTP) and TC exercise were 89% and 83%, respectively.

Data show that GTP supplementation provided higher values for serum bone-specific alkaline phosphatase (bone formation biomarker) after 4 weeks (P = 0.03), while Tai Chi exercise provided higher values for BAP after 12 weeks (P = 0.04) and marginally (P = 0.09) after 24 weeks. Neither GTP supplementation nor Tai Chi exercise had any effect on serum TRAP (bone resorption biomarker) levels. BMD could not be justified as an outcome in such a short-term study where changes in BMD were not expected to be detectable. Although the effects of GTP on bone biomarkers are encouraging and promising, a longer-term clinical study in which BMC and BMD are assessed is needed to confirm the bone protective effects of GTP in postmenopausal women.

5. Mechanisms of action

Numerous studies have indicated that excessive oxidative stress is a pivotal pathogenic factor [33] for age-related bone loss in mice [34], rats [16], and the elderly population [35,36] resulting in increased osteoblast and osteocyte apoptosis, and decreased osteoblast population and bone formation rate [34]. Oxidative stress suppresses osteoblastic differentiation [37,38] via extracellular signal-regulated kinases (ERK) and ERK-dependent NF-κB signaling pathways [39]. Osteoblasts can produce antioxidants, such as glutathione peroxidase, to protect against reactive oxygen species (ROS) [40], and transforming growth factor-β involved in reduction of bone resorption [41]. ROS are also involved in bone resorption by directly contributing osteoclast-generated superoxide to bone degradation [42], and oxidative stress increases differentiation and function of osteoclasts [43]. A tight association between excessive production of oxidative stress and the pathogenesis of osteoporosis in humans was shown in a variety of bone loss models induced by aging [36], estrogen deficit [35,36], obesity [44], advanced chronic kidney disease [45], atherosclerosis [44], and diabetes [44,46].

Similar to the impact of oxidative stress on bone loss, systemic chronic inflammation also results in the development of osteoporosis. Chronic inflammation causes continuous activation of both the innate and adaptive immune systems that disturb the balance between bone formation and resorption, and then triggers inflammatory bone loss [47]. Several inflammatory mediators, such as tumor necrosis factor (TNF)-α, IL-1, IL-6, IL-7, IL-17, prostaglandin E2 produced by macrophages, T cells or fibroblasts, stimulate osteoclast formation and bone resorption by inducing the expression of M-CSF and RANKL. In addition, TNF induces Dickkopf 1, a Wnt antagonist, which blocks bone formation through inhibiting the differentiation of osteoblasts from mesenchymal precursors. On the other hand, TNF also induces the expression of sclerostin in osteocytes, a potent down-regulator of bone formation [47]. An epidemiologic study demonstrated a positive association between inflammatory markers and incident non-traumatic fractures in an elderly population [48]. Clinical sequelae of systemic chronic inflammation on bone loss have also been shown in different rheumatic diseases, such as rheumatoid arthritis, systemic
lupus erythematosus and spondyloarthritides [47]. Since excessive oxidative stress and chronic inflammation contribute to bone loss, it is important to understand the role of antioxidants and anti-inflammatory agents in dietary supplements or functional foods, such as green tea, in mitigating bone loss during the development of osteoporosis. Green tea extract, a non-oxidized and non-fermented product, is rich in phenolic compounds, such as EGCG ([most abundant component]), EC, EC, EG and catechins [6], which act as antioxidant and anti-inflammatory agents. Therefore, the beneficial effects of green tea on bone may be mediated, in part, through its antioxidant and anti-inflammatory properties.

The abilities of green tea or its active components to increase indices of bone formation (osteoblastogenesis) have been supported by the following evidences: (1) When osteoblastic MC3T3-E1 cells treated with (+)-catechin at 10−4 to 10−5 mol/L for 48 h, (+) catechin increased osteoblastic survival and increased osteoblastic apoptosis through an inhibition of TNF-α and IL-6 production [49]. (2) When antler progenitor cells treated with EGCG at 25 μmol/L for 24 h, EGCG enhanced proliferation and differentiation of bone cells, as shown in an elevation in alkaline phosphatase activity, via Wnt signaling pathway [50]. (3) When osteoblastic MC3T3-E1 cells treated with EGCG at 30 μmol/L for 60 min, EGCG favored osteoblastogenesis via suppressing transforming growth factor-β-stimulated heat shock protein 27 induction that mediated via SAPK/JNK pathway [51]. (4) When MC3T3-E1 cells treated with EGCG at 100 μmol/L for 60 min, EGCG increased osteoblastogenesis via inhibiting prostaglandin D2–induced heat shock protein 27 induction that mediated through p44/p42 MAPK pathway [52]. (5) When MC3T3-E1 cells treated with EGCG at 10–100 μmol/L for 60 min, EGCG stimulated osteoblastogenesis via increasing prostaglandin-F2-induced vascular endothelial growth factor synthesis that involved in SAPK/JNK activation [53,54]. (6) When SaOS-2 cells treated with EGCG at 1–5 μmol/L for up to 17 days, EGCG promoted formation of mineralized bone nodules including area and number, via suppressing Runt-related transcription factor-2 (Runx2) expression [55,56]. In addition, similar results in mineralization findings were also observed in D1 cells treated with EGCG at 10 μmol/L for up to 4 weeks [57].

On the other hand, the abilities of green tea and its bioactive components to suppress indices of bone resorption (osteoclastogenesis) have been demonstrated by the following evidences: (1) When osteoclast-like multinucleated cells treated with EGCG at 25–100 μmol/L for 3 days, EGCG increased apoptosis of osteoclasts but without affecting osteoblasts via enhancing single strand DNA damage [58,60], via inducing the Fenton reaction [58,59], or via increasing caspase-3 activation [61]. (2) When RAW264.7 cells treated with EGCG at 10–100 μmol/L for 24 h, EGCG decreased survival of osteoclasts, increased apoptosis of osteoclasts, and decreased osteoclastic differentiation via decreasing RANKL-induced NF-κB transcriptional and nuclear translocation [62,64–66]. (3) When bone marrow with primary osteoclasts cells treated with EGCG at 20 μmol/L for 3 days, EGCG suppressed the formation of osteoclasts via inhibiting expression of matrix metalloproteinase-9 [63]. (4) When embryonic mouse calvaria treated with EGCG at 0.1–1 mmol/L for 18 h, EGCG inhibited bone resorption and prevented osteoclast activation by acting on bone collagen that could well render bone tissue less prone to resorption [67].

6. Summary and future research

Osteoporosis is the result of a metabolic imbalance of faster resorption than formation. To date our animal studies strongly suggest that green tea has a pronounced effect on bone in terms of bone preservation as shown by higher bone mass [BMC and BMD], trabecular bone volume, number, and thickness, and lower trabecular separation through enhancing bone formation and suppressing bone resorption, resulting in greater bone strength. Although these results are mostly obtained from rat studies, we anticipate that the observations of these animal studies will be confirmed in human studies. Our short-term translational study showing GTP favored bone formation at an early intervention stage would extend the findings from animals to the human population. In future human studies, green tea and its active ingredients should be tested long term through evaluating the bioavailability via validated biofluid biomarkers and through assessing the efficacy in terms of bone mass (BMC and BMD), micro-architectue (cancellous and endocortical bones), and bone strength via advanced imaging technology in order to confirm their benefits to osteoporosis.

Acknowledgment

The preparation of this review was supported by NIH/NCCAM grant R21AT003735, Laura W. Bush Institute for Women’s Health, and Winthrop-University Hospital.

References


